Skip to main content
Fig. 13 | Clinical Epigenetics

Fig. 13

From: Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma

Fig. 13

Venetoclax and chidamide selectively target primary B lymphoma cells while sparing normal PBMCs in vitro. Primary B-cell lymphoma samples (n = 15) and peripheral blood samples from healthy donors (n = 7) were collected. Flow cytometry analysis was performed after staining with the Annexin V/PI kit, the combined treatment of venetoclax and chidamide increased the death level of primary B lymphoma cells (n = 15) while sparing normal PBMCs (n = 7). Data were represented as mean ± SD. **p < 0.01, ****p < 0.0001 and ns (not significant) by one‐way ANOVA

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us